LYRM1

Across TCGA pan-cancer cohorts, LYRM1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LYRM1 data layer compared with 17 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher LYRM1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LYRM1 expression acts as an unfavorable survival marker.

BRCA, MESO, and SARC are the cancer types where LYRM1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.123	0.924	<.001	24	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

LYRM1–BRCA (OS)

Open the BRCA breakdown →